Abstract 1752P
Background
MTC is a rare disease with limited systemic therapeutic options. This study described real-world care patterns for pts with MTC in France, Germany, Italy, Spain and the UK.
Methods
Data were drawn from the Adelphi Thyroid Cancer Disease Specific ProgrammeTM – a point-in-time survey conducted between July-December 2020 with oncologists and endocrinologists in clinical practice. Physicians completed patient record forms for up to the next 4 consulting adult pts with locally advanced or metastatic MTC, including data on demographics, clinical characteristics, tx patterns and rationales, and RET mutation testing.
Results
153 physicians provided data for 275 pts with MTC (mean age 60 years, 53% female, mean 29.4 months since diagnosis). 186 (68%) were tested for RET mutations and had a known result; of these, 79 (42%) were RET+ and 107 (58%) were RET-. Mean (SD) ages of pts with RET+ and RET- MTC at data abstraction were 56.0 (10.9) and 62.0 (11.0) years, and 28% and 1% respectively had a family history of thyroid cancer. 35 (44%) of pts with RET+ MTC and 45 (42%) with RET- MTC had surgery during locally advanced disease. Of these, most common surgery was total thyroidectomy (RET+; 28 (80%), RET-; 36 (80%)). 15 (19%) of pts with RET+ and 11 (10%) with RET- MTC had surgery during metastatic disease. Of these, the most common surgery was neck lymph node removal (RET+ 8 (53%), RET- 4 (36%)). Of 67 pts (36 RET+, 31 RET-) with known dates of advanced diagnosis and tx initiation, mean (SD) time between these events was 1.3 (2.7) and 0.9 (3.9) years respectively. As first line, 37 RET+ (47%) and 44 RET- (41%) received targeted therapy only (cabozantinib, vandetanib or larotrectinib), 14 (18%) and 10 (9%) received targeted therapy plus hormone replacement therapy respectively. 15 (19%) of pts with RET+ and 23 (21%) with RET- MTC discontinued first line tx. The most frequent reason was disease progression (40% of all pts).
Conclusions
Surgery and adjuvant tx patterns were similar between pts with RET+ and RET- MTC, indicating a need for broader education among physicians on considering more tailored treatment approaches for each group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adelphi Group.
Funding
Adelphi Group.
Disclosure
A. Rider: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. L.M. Hess: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. T. Puri: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. M. Jen: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. R. Williams: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. I. Sanderson: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. U. Kiiskinen: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company.